Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

通过转导单个白血病B细胞诱导对嵌合抗原受体T细胞疗法的耐药性

阅读:4
作者:Marco Ruella # ,Jun Xu # ,David M Barrett # ,Joseph A Fraietta ,Tyler J Reich ,David E Ambrose ,Michael Klichinsky ,Olga Shestova ,Prachi R Patel ,Irina Kulikovskaya ,Farzana Nazimuddin ,Vijay G Bhoj ,Elena J Orlando ,Terry J Fry ,Hans Bitter ,Shannon L Maude ,Bruce L Levine ,Christopher L Nobles ,Frederic D Bushman ,Regina M Young ,John Scholler ,Saar I Gill ,Carl H June ,Stephan A Grupp ,Simon F Lacey ,J Joseph Melenhorst

Abstract

We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion with CD19- leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was unintentionally introduced into a single leukemic B cell during T cell manufacturing, and its product bound in cis to the CD19 epitope on the surface of leukemic cells, masking it from recognition by and conferring resistance to CTL019.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。